Health Condition 1: K740- Hepatic fibrosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. PatientS with written informed consent 2. Patients of chronic liver disease undergoing liver transplantation are admitted to the liver transplant ICU on the ongoing infusion of norepinephrine. 3.Age group of 18-60 years
Exclusion criteria
Exclusion criteria: • Patient refusal •Concomitant therapy with epinephrine, dobutamine, or dopamine. •Recurrent cardiac arrhythmia •Reduced ventricular systolic function - left (ejection fraction
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine whether EaDyn is able to predict a decrease in MAP of more than 10% after reduction of norepinephrine dose in a cohort of postoperative liver transplant recipients.Timepoint: -baseline -15 mins after reduction of norepinephrine -30 mins after reduction of norepinephrine | — |
Secondary
| Measure | Time frame |
|---|---|
| -To describe EaDyn variations induced by change in vasopressors dose -To study variation of hemodynamic parameters induced by change in vasopressors dose Timepoint: -baseline -15 mins after reduction of norepinephrine -30 mins after reduction of norepinephrine | — |
Countries
India
Contacts
Mahatma Gandhi Medical College and Hospital, Jaipur